Reed R C, Schwartz H J
J Pharmacokinet Biopharm. 1984 Jun;12(3):315-31. doi: 10.1007/BF01061723.
We examined the influence of a large-volume, therapeutic antacid regimen, administered for three full days, on the steady-state bioavailability of a conventional-release and sustained-release theophylline product, Aminophyllin and Theodur, respectively. Nine stable asthmatics voluntarily completed a four-phase investigation requiring a total stay of 12 days in the Clinical Research Unit. The treatments consisted of administration of the formulations mentioned with and without antacids to each patient in a randomized sequence. Four patients participated in an additional phase where antacids were administered q2h around the clock for three days. After coadministration of theophylline plus antacids for two days, theophylline therapy was discontinued while numerous blood samples were obtained over 22 hr and analyzed for theophylline content via radioimmunoassay. Antacids had no predictable, consistent influence on theophylline absorption rate as determined by the absorption rate constant, the time to maximal theophylline concentration, or the lag time for theophylline absorption. Antacids had no detectable influence on theophylline elimination half-life and had no consistent, statistically significant effect on the extent of theophylline bioavailability, according to measurements of maximal concentration, AUC measured over the appropriate steady-state dosing interval, or elimination-rate adjusted AUC. The substantial intraindividual changes for all parameters of theophylline bioavailability that occurred for control and treatment phases likely represent spontaneous, random between-day variability in theophylline disposition independent of antacid administration, as evidenced by the comparability of the percent coefficient of variation for parameters of bioavailability across all phases. Our data demonstrate that therapeutic antacid administration has no effect on steady-state theophylline bioavailability and does not alter the intrinsic variability in theophylline absorption. Based on the results of our data, it is unlikely that a clinically significant (greater than 20%) decrease in theophylline absorption would occur in any patient treated intensively with antacids concurrently.
我们研究了连续三天给予大剂量治疗性抗酸方案对常规释放型和缓释型茶碱产品(分别为氨茶碱和茶喘平)稳态生物利用度的影响。九名病情稳定的哮喘患者自愿完成了一项分四个阶段的研究,需要在临床研究室总共停留12天。治疗方法是将上述制剂与抗酸剂一起或不与抗酸剂一起,以随机顺序给予每位患者。四名患者参与了额外的一个阶段,在此阶段中,抗酸剂每2小时全天候给药,持续三天。在茶碱与抗酸剂联合给药两天后,停止茶碱治疗,同时在22小时内采集大量血样,并通过放射免疫测定法分析茶碱含量。通过吸收速率常数、达到最大茶碱浓度的时间或茶碱吸收的滞后时间确定,抗酸剂对茶碱吸收速率没有可预测的、一致的影响。根据最大浓度、在适当的稳态给药间隔内测得的AUC或消除率调整后的AUC测量结果,抗酸剂对茶碱消除半衰期没有可检测到的影响,对茶碱生物利用度的程度也没有一致的、具有统计学意义的影响。在对照期和治疗期,茶碱生物利用度的所有参数在个体内发生的显著变化可能代表茶碱处置过程中自发的、随机的日间变异性,与抗酸剂给药无关,这一点可通过所有阶段生物利用度参数变异系数百分比的可比性得到证明。我们的数据表明,给予治疗性抗酸剂对稳态茶碱生物利用度没有影响,也不会改变茶碱吸收的内在变异性。根据我们的数据结果,同时接受抗酸剂强化治疗的任何患者,茶碱吸收不太可能出现临床上显著的(大于20%)下降。